

EMERGERS PUBLISHES UPDATED ANALYSIS FOR PROLIGHT DIAGNOSTICS

Emergers has updated its analysis of Prolight Diagnostics, noting among other things that the investment case has strengthened due to the fully subscribed rights issue and strong international interest following the presentation of the fully operational commercial prototype at the international ADLM congress in the US.

Read the article here: <https://www.emergers.se/prolight-m25/>

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Emergers publishes updated analysis for Prolight Diagnostics